Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Bipolar Disorder II Depression and Suicidality
NCT06706232Phase 2Recruiting
- Sponsor
- UTHealth Houston
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in Bipolar II disorder (BP-II), major depressive disorder (MDD), Suicidality, sponsored by UTHealth Houston. Started Jul 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
Bipolar II disorder (BP-II)major depressive disorder (MDD)Suicidality
Beyond the preview
Go deeper on NCT06706232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706232.